Prevalence of methylenetetrahydrofolate gene (MTHFR) C677T polymorphism among chronic hemodialysis patients and its association with cardiovascular disease: A cross-sectional analysis

Clinical and Experimental Nephrology

Volumn 13, Issue 5, 2009, Pages 501-507

  Ibrahim, Salwa ^a   El Dessokiy, Ola ^b  

^a CAIRO UNIVERSITY   (Egypt)

^b Cairo University   (Egypt)

Author keywords

Cardiovascular disease; Hemodialysis; Hyperhomocysteinemia; Methylenetetrahydrofolate reductase gene polymorphism

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); CYANOCOBALAMIN;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DNA POLYMORPHISM; FEMALE; FOLIC ACID BLOOD LEVEL; GENE FREQUENCY; GENE MUTATION; HEART INFARCTION; HEMODIALYSIS; HUMAN; HYPERTENSION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; STROKE; TRANSIENT ISCHEMIC ATTACK;

ADULT; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; POLYMORPHISM, GENETIC; RENAL DIALYSIS;

EID: 70349679151     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-009-0194-2     Document Type: Article

References (41)

1. Lindholm NB, Stenvinkel P. End stage renal disease-not an equal opportunity disease: the role of genetic polymorphism. J Intern Med. 2005;258:1-12.
2. AS Go GM Chertow D Fan CE McCulloch CY Hsu 2004 Chronic kidney disease and the risks of death, cardiovascular events and hospitalization N Eng J Med 351 1296 1305 10.1056/NEJMoa041031 1:CAS:528:DC%2BD2cXnvFSgtr8%3D (Pubitemid 39268908)
3. Satko SG, Freedman BI, Moossavi S. Genetic factors in end stage renal disease. Kidney Int. 2005;67(Suppl 94):S46-9.
4. P Frost HJ Blom R Milos P Goyette CA Sheppard RG Matthews, et al. 1995 A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase Nat Genet 10 111 113 10.1038/ng0595-111
5. L Brattstrom 1997 Common mutation in the methylenetetrahydrofolate reductase gene offers no support for mild hyperhomocysteinemia being a causal risk factor for cardiovascular disease Circulation 96 3805 3807 9396508 1:STN:280:DyaK1c%2FlslWqtg%3D%3D
6. LA Kluijtmans LP van den Heuvel GH Boers, et al. 1996 Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease Am J Hum Genet 58 35 41 8554066 1:CAS:528: DyaK28XkvFCntA%3D%3D
7. Morita H, Taguchi JI, Kurihara H, et al. Genetic polymorphism of 5,10-methylenetetrahydrofolate reductase (MTHFR) as a risk factor for coronary artery disease. Circulation. 1997;95:2032-6.
8. S Neugebauer T Baba T Watanabe 1997 Defective homocysteine metabolism as a risk factor for diabetic retinopathy Lancet 349 473 474 9040583 10.1016/S0140-6736(05)61185-3 1:STN:280:DyaK2s7pt12qsw%3D%3D
9. P Ksiazek A Bednarek-Skublewska M Buraczynska 2004 The C677T methylenetetrahydrofolate reductase gene mutation and nephropathy in type 2 diabetes mellitus Med Sci Monit 10 2 BR47 BR51 14737040 1:CAS:528: DC%2BD2cXitlaqtrc%3D
10. G Hasegawa H Obayashi K Kamiuchi M Nakai T Kanatsuna M Yamaguchi T Tanaka H Shigeta M Fujii T Yoshikawa N Nakamura 2003 The association between end-stage diabetic nephropathy and methylenetetrahydrofolate reductase genotype with macroangiopathy in type 2 diabetes mellitus Exp Clin Endocrinol Diabetes 111 132 138 12784186 10.1055/s-2003-39785 1:CAS:528:DC%2BD3sXks1GrsLw%3D (Pubitemid 36682051)
11. Koupepidou P, Deltas C, Christofides TC, Athanasiou Y, Zouvani I, Pierides A. The MTHFR 677TT and 677CT/1298AC genotypes in Cypriot patients may be predisposing to hypertensive nephrosclerosis and chronic renal failure. Int Angiol. 2005;24(3):287-94.
12. S Tyszko B Rutkowski WH Horl 2005 Methylenetetrahydrofolate reductase gene polymorphisms in essential hypertension relation with: the development of hypertensive end-stage renal disease Am J Hypertens 18 11 1442 1448 16280279 10.1016/j.amjhyper.2005.05.012 (Pubitemid 41566673)
13. RN Foley PS Parfrey MJ Samak 1998 Clinical epidemiology of cardiovascular disease in chronic renal disease Am J Kidney Dis 32 5 Suppl 3 S112 9820470 10.1053/ajkd.1998.v32.pm9820470 1:STN:280:DyaK1M%2Fjs1emtA%3D%3D
14. M Fodinger C Mannhalter G Wolfl I Pabinger E Muller R Schmid, et al. 1997 Mutation (677 C to T) in the methylenetetrahydrofolate reductase gene aggravates hyperhomocysteinemia in haemodialysis patients Kidney Int 52 517 523 9264011 10.1038/ki.1997.362 1:CAS:528:DyaK2sXls1Wmt7c%3D
15. A Pastore R Massoud C Motti A Lo Russo G Fucci C Cortese, et al. 1998 Fully automated assay for total homocysteine, cysteine, cysteinylglycine, glutathione, cysteamine, and 2 mercaptopropionylglycine in plasma and urine Clin Chem 44 825 832 9554495 1:CAS:528:DyaK1cXisFSitrg%3D
16. Boger CA, Stubanus M, Haak T, Gotz AK, Christ J, Hoffmann U, et al. Effect of MTHFR C677T genotype on survival in type 2 diabetes patients with end stage diabetic nephropathy. Nephrol Dial Transplant. 2007;22:154-62.
17. MJ Zychma J Gumprecht W Grzeszczak E Zukowska-Szczechowska 2002 End-stage renal disease study group Nephron 92 1 235 239 12187113 10.1159/000064458 1:CAS:528:DC%2BD38XmtlCjsb0%3D (Pubitemid 34983904)
18. H Kimura F Gejyo S Suzuki R Miyazaki 2000 The C677T methylenetetrahydrofolate reductase gene mutation in haemodialysis patients J Am Soc Nephrol 11 5 885 893 10770966 1:CAS:528:DC%2BD3cXjt1Sksrs%3D
19. R Danis S Ozmen D Akin F Celik O Yazanel 2008 Predictive factors of cardiovascular disease in patients on maintenance haemodialysis Dial Transplant 37 2 58 66 10.1002/dat.20189
20. F Aucella M Margaglione E Grandone Genetic Polymorphism in Dialysis Study Group, et al. 2005 The C677T methylenetetrahydrofolate reductase gene mutation does not influence cardiovascular risk in the dialysis population: results of a multicentre prospective study Nephrol Dial Transplant 20 382 386 15618240 10.1093/ndt/gfh620 1:CAS:528:DC%2BD2MXovV2itQ%3D%3D (Pubitemid 40276895)
21. EM Wrone JL Zehnder JM Hornberger LM McCann NS Coplon SP Fortmann 2001 An MTHFR variant, homocysteine, and cardiovascular comorbidity in renal disease Kidney Int 60 3 1106 1113 11532106 10.1046/j.1523-1755.2001.0600031106.x 1:CAS:528:DC%2BD3MXmvFKjtb0%3D (Pubitemid 34205811)
22. M Fukasawa K Matsushita M Kamiyama, et al. 2003 The methylenetetrahydrofolate reductase C677T point mutation is a risk factor for vascular access thrombosis in haemodialysis patients Am J Kidney Dis 41 3 637 642 12612987 10.1053/ajkd.2003.50125 1:CAS:528:DC%2BD3sXisVOjurc%3D (Pubitemid 36278381)
23. PS Lim WR Hung YH Wei 2001 Polymorphism in methylenetetrahydrofolate reductase gene: its impact on plasma homocysteine levels and carotid atherosclerosis in ESRD patients receiving haemodialysis Nephron 87 3 249 256 11287760 10.1159/000045922 1:CAS:528:DC%2BD3MXivVajsLk%3D (Pubitemid 32268566)
24. Y Yao H Liu X Zhang, et al. 2002 Methylenetetrahydrofolate reductase gene polymorphism and plasma homocysteine levels in haemodialysis patients Zhonghua Nei Ke Za Zhi 41 8 522 525 12421498 1:CAS:528:DC%2BD3sXosFKrurc%3D
25. Domenici FA, Vannucchi MT, Simoes-Ambrosio LM, Vannucchi H. Hyperhomocysteinemia and polymorphisms of the methylenetetrahydrofolate gene in hemodialysis and peritoneal dialysis patients. Mol Nutr Food Res. 2007;51(11):1430-1436.
26. A Bednarek-Skublewaka M Buraczynska S Wawrzycki, et al. 2002 Some aspects of homocysteine metabolism in haemodialysis patients Pol Arch Med Wewm 108 5 1041 1047
27. 12 levels, and C677T MTHFR mutation in children with renal failure. Pediatr Nephrol. 2003;18(3):225-9.
28. R Tremblay A Bonnardeaux D Geadah, et al. 2000 Hyperhomocysteinemia in haemodialysis patients: effects of 12-month supplementation with hydrosoluble vitamins Kidney Int 58 2 851 858 10916110 10.1046/j.1523-1755.2000.00234.x 1:CAS:528:DC%2BD3cXlvFagsLo%3D (Pubitemid 30620035)
29. W Anwar JL Gueant L Abdelmouttaleb, et al. 2001 Hyperhomocysteinemia is related to residual glomerular filtration and folate, but not to methylenetetrahydrofolate reductase and methionine synthase polymorphisms, in supplemented end-stage renal disease patients undergoing haemodialysis Clin Chem Lab Med 39 8 747 752 11592445 10.1515/CCLM.2001.124 1:CAS:528: DC%2BD3MXotVSrs7s%3D (Pubitemid 32894422)
30. P Jungers P Chauveau O Bandin, et al. 1997 Hyperhomocysteinemia is associated with atherosclerotic occlusive arterial accidents in predialysis chronic renal failure patients Miner Electrolyte Metab 23 170 173 9387110 1:CAS:528:DyaK2sXntFymsb4%3D (Pubitemid 27475338)
31. BJ Manns ED Burgess ME Hyndman, et al. 1999 Hyperhomocysteinemia and the prevalence of atherosclerotic vascular disease in patients with end stage renal disease Am J Kidney Dis 34 669 677 10516348 10.1016/S0272-6386(99)70392-6 1:STN:280:DyaK1MvkvVSqug%3D%3D
32. F Mallamaci C Zoccali G Tripepi, et al. 2002 CREED investigators. Hyperhomocysteinemia predicts cardiovascular outcomes in haemodialysis patients Kidney Int 61 609 614 11849403 10.1046/j.1523-1755.2002.00144.x (Pubitemid 34102603)
33. ME Suliman P Stenvinkel O Heimburger, et al. 2002 Plasma sulphur amino acids in relation to cardiovascular disease, nutritional status, and diabetes mellitus in patients with chronic renal failure at start of dialysis therapy Am J Kidney Dis 40 480 488 12200798 10.1053/ajkd.2002.34887 1:CAS:528: DC%2BD38Xntl2ltLY%3D (Pubitemid 34971275)
34. ME Suliman AR Qureshi P Barany, et al. 2000 Hyperhomocysteinemia, nutritional status, and cardiovascular disease in haemodialysis patients Kidney Int 57 1727 1735 10760109 10.1046/j.1523-1755.2000.00018.x 1:STN:280: DC%2BD3c3itlKjtQ%3D%3D (Pubitemid 30207932)
35. 12 levels, and C677T MTHFR mutation in children with renal failure. Pediatr Nephrol. 2003;18:225-9.
36. 12 decreases, but does not normalize, homocysteine and methylmalonic acid in end-stage renal disease: a link with glycine metabolism and possible explanation of hyperhomocysteinemia in end stage renal disease Metabolism 52 2 168 172 12601627 10.1053/meta.2003.50022 1:CAS:528:DC%2BD3sXhtlCltrs%3D (Pubitemid 36388838)
37. AK Cheung MJ Sarnak G Yan, et al. 2000 Atherosclerotic cardiovascular disease risks in chronic haemodialysis patients Kidney Int 58 1 353 362 10886582 10.1046/j.1523-1755.2000.00173.x 1:STN:280:DC%2BD3cvgs1Sjuw%3D%3D (Pubitemid 30429882)
38. EG Lowrie NL Lew 1990 Death risk in haemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities Am J Kidney Dis 15 458 482 2333868 1:STN:280:DyaK3c3ktVaitg%3D%3D
39. K Kalantar-Zadeh G Block MH Humphreys, et al. 2003 Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients Kidney Int 63 793 808 12631061 10.1046/j.1523-1755.2003.00803.x (Pubitemid 36315558)
40. P Degoulet M Legrain I Reach, et al. 1982 Mortality risk factors in patients treated by chronic haemodialysis: report of the diaphane collaborative study Nephron 31 103 110 7121651 10.1159/000182627 1:STN:280: DyaL3s%2FhtlWjtg%3D%3D
41. K Iseki F Miyasato K Tokuyama, et al. 1997 Low diastolic blood pressure, hypoalbuminemia, and risk of death in a cohort of chronic haemodialysis patients Kidney Int 51 1212 1217 9083288 10.1038/ki.1997.165 1:STN:280: DyaK2s3js1GqsA%3D%3D